Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy

Cytokine

Volumn 27, Issue 2-3, 2004, Pages 58-65

  Bozcuk, Hakan ^a,b   Uslu, Gülcan ^a   Samur, Mustafa ^a   Yildiz, Mustafa ^a   Özben, Tomris ^a   Özdoǧan, Mustafa ^a   Artaç, Mehmet ^a   Altunbaş, Hasan ^a   Akan, Ilhan ^a   Savaş, Burhan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b Department of Internal Medicine ^*  (Turkey)

Author keywords

Breast cancer; Chemotherapy; IL 6; Insulin; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; INSULIN; INTERLEUKIN 6; NAVELBINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FASTING; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042828288     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2004.04.002     Document Type: Article

References (32)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182
2. Gusterson B.A., Gelber R.D., Goldhirsch A., Price K.N., Save-Soderborgh J., Anbazhagan R., et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 10:1992;1049-1056
3. Pinto A.E., Andre S., Pereira T., Nobrega S., Soares J. C-erbB-2 overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol. 12:(4):2001;525-533
4. Bozcuk H., Uslu G., Pestereli E., Samur M., Ozdogan M., Karaveli S., et al. Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators. Breast Cancer Res Treat. 68:2001;239-248
5. Nicholson S., Richard J., Sainsbury C., Halcrow P., Kelly P., Angus B., et al. Epidermal growth factor receptor (EGFr): results of a 6-year follow-up study in breast cancer with emphasis on the node negative subgroup. Br J Cancer. 63:1991;146-150
6. Nicholson S., Halcrow P., Sainsbury J.R., Angus B., Chambers P., Farndon J.R., et al. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer. 58:1988;810-814
7. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., et al. Circulating concentrations of IGF1 and risk of breast cancer. Lancet. 351:1998;1393-1396
8. Stoll B.A. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord. 26:2002;747-753
9. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M.E., Koo J., Madarnas Y., et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 20:(1):2002;42-51
10. Lotz M., Jirik F., Kabouridis P., Tsoukas C., Hirano T., Kishimoto T., et al. B cell stimulating factor 2/interleukin-6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med. 167:(3):1988;1253-1258
11. Leary A.G., Ikebuchi K., Hirai Y., Wong G.G., Yang Y.C., Clark S.C., et al. Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha. Blood. 71:(6):1988;1759-1763
12. Wong G.G., Witek-Giannotti J.S., Temple P.A., Kriz R., Ferenz C., Hewick R.M., et al. Stimulation of murine hemopoietic colony formation by human IL-6. J Immunol. 140:(9):1988;3040-3044
13. Van Damme J., Van Beeumen J., Decock B., Van Snick J., De Ley M., Billiau A. Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6. J Immunol. 140:(5):1988;1534-1541
14. Zhang G.J., Adachi I. Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19:1999;1427-1432
15. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today. 11:(12):1990;443-449
16. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol. 62:(1 pt 2):1992;60-65
17. Watson J.M., Berek J.S., Martinez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol. 49:(1):1993;8-15
18. Vilcek J., Lee T.H. Tumour necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem. 266:(12):1991;7313- 7316
19. Sheen-Chen S.M., Chen W.J., Eng H.L., Chou F.F. Serum concentration of tumour necrosis factor in patients with breast cancer. Breast Cancer Res Treat. 43:1997;211-215
20. Radziuk J. Insulin sensitivity and its measurement: structural commonalties among the methods. J Clin Endocrinol Metab. 85:(12):2000;4426-4433
21. James K., Eisenhauer E., Christian M., Terenziani M., Vena D., Muldal A., et al. Measuring response in solid tumours: unidimensional versus bidimensional measurement. J Natl Cancer. 91:(6):1999;523-528
22. Parmar M.K.B., Machin D. Survival analysis: a practical approach. 1999;John Wiley and Sons, Great Britain
23. Demirbas B., Guler S., Cakir B., Culha C., Aral Y. Plasma tumour necrosis factor-alpha and insulin resistance in non-diabetic hypertensive subjects. Horm Res. 58:(6):2002;283-286
24. Benoy I., Solgado R., Colpoert C., Weytjens R., Vermeulen P.B., Dirix C.Y. Serum interleukin-6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2:(4):2002;311-315
25. Shen W.H., Zhou J.H., Broussard S.R., Freund G.G., Dantzer R., Kelley K.W. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res. 62:(16):2002;4746-4756
26. Morgan M., Williams B.A., Blay J., Hoskin D.W. Chemosensitization of T-47D breast carcinoma cells to TRAIL and Fas receptor-induced killing. Anticancer Res. 22:(2A):2002;673-676
27. Zhou G., Kuo M.T. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem. 272:(24):1997;15174-15183
28. Pandini G., Vigneri R., Costantino A., Frasca F., Ippolito A., Fujita-Yamaguchi Y., et al. Insulin and insulin-like growth factor-I (IGF-1) receptor overexpression in breast cancers leads to insulin/IGF-1 hybrid receptor overexpression: evidence for a second mechanism of IGF-1 signalling. Clin Cancer Res. 5:(7):1999;1935-1944
29. Ryberg M., Nielsen D., Osterlind K., Skovsgaard T., Dombernowsky P. Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol. 12:(1):2001;81-87
30. Schneeweiss A., Hensel M., Goerner R., Khbeis T., Hohaus S., Egerer G., et al. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. Stem Cells. 19:(2):2001;151-160
31. Tsuda H., Tsugane S., Fukutomi T., Nanasawa T., Yamamoto H., Hirohashi S. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histological grade and amplification of the c-erbB-2 proto-oncogene. Jpn J Clin Oncol. 22:(4):1992;244-249
32. Niskanen E., Blomqvist C., Franssila K., Hietanen P., Wasenius V.M. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer. 76:(7):1997;917-922